Skip to content

Author

J. Oldenburg

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors.

BACKGROUND Denecimig (Mim8) is an activated factor VIII mimetic, fully human, bispecific IgG4 antibody in development for subcutaneous prophylaxis in patients with haemophilia A (HA) with/without inhibitors. OBJECTIVE To evaluate the safety and patient experience of a direct switch from emicizumab to denecimig prophy...

Cédric Hermans, Gary Benson, D. Matino et al. · 1 citation
Open access Jul 2026

In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway.

In vivo evidence is provided that common THBD and PROCR variants modulate PC pathway function, establishing the APC response as a sensitive endpoint for subtle genetic effects beyond FVL and not associated with THBD 1418C>T.

S. Reda, N. Schwarz, Sebastian Eckert et al. · 0 citations
Open access Aug 2026

AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins

This work presents a scalable mammalian cell-display workflow to identify AI-designed minibinders against cancer surface targets and identifies biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.

B. Broske, B. McEnroe, S. C. Frechen et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.